First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis.
Biomarkers commonly assessed in prenatal screening have been associated with a number of adverse perinatal and birth outcomes. However, it is not clear whether first trimester measurements of prenatal screening biomarkers are associated with subsequent risk of gestational diabetes mellitus (GDM). We...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6062092?pdf=render |
| _version_ | 1811330682297778176 |
|---|---|
| author | Brittney M Donovan Nichole L Nidey Elizabeth A Jasper Jennifer G Robinson Wei Bao Audrey F Saftlas Kelli K Ryckman |
| author_facet | Brittney M Donovan Nichole L Nidey Elizabeth A Jasper Jennifer G Robinson Wei Bao Audrey F Saftlas Kelli K Ryckman |
| author_sort | Brittney M Donovan |
| collection | DOAJ |
| description | Biomarkers commonly assessed in prenatal screening have been associated with a number of adverse perinatal and birth outcomes. However, it is not clear whether first trimester measurements of prenatal screening biomarkers are associated with subsequent risk of gestational diabetes mellitus (GDM). We aimed to systematically review and statistically summarize studies assessing the relationship between first trimester prenatal screening biomarker levels and GDM development. We comprehensively searched PubMed/MEDLINE, EMBASE, CINAHL, and Scopus (from inception through January 2018) and manually searched the reference lists of all relevant articles. We included original, published, observational studies examining the association of first trimester pregnancy associated plasma protein-A (PAPP-A) and/or free β-human chorionic gonadotropin (free β-hCG) levels with GDM diagnosis. Mean differences were calculated comparing PAPP-A and free β-hCG multiples of median (MoM) levels between women who developed GDM and those who did not and were subsequently pooled using two-sided random-effects models. Our meta-analysis of 13 studies on PAPP-A and nine studies on free β-hCG indicated that first trimester MoM levels for both biomarkers were lower in women who later developed GDM compared to women who remained normoglycemic throughout pregnancy (MD -0.17; 95% CI -0.24, -0.10; MD -0.04; 95% CI -0.07-0.01). There was no evidence for between-study heterogeneity among studies on free β-hCG (I2 = 0%). A high level of between-study heterogeneity was detected among the studies reporting on PAPP-A (I2 = 90%), but was reduced after stratifying by geographic location, biomarker assay method, and timing of GDM diagnosis. Our meta-analysis indicates that women who are diagnosed with GDM have lower first trimester levels of both PAPP-A and free β-hCG than women who remain normoglycemic throughout pregnancy. Further assessment of the predictive capacity of these biomarkers within large, diverse populations is needed. |
| first_indexed | 2024-04-13T16:07:27Z |
| format | Article |
| id | doaj.art-f4f94298299f4f2b87921160d8c96427 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T16:07:27Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f4f94298299f4f2b87921160d8c964272022-12-22T02:40:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01137e020131910.1371/journal.pone.0201319First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis.Brittney M DonovanNichole L NideyElizabeth A JasperJennifer G RobinsonWei BaoAudrey F SaftlasKelli K RyckmanBiomarkers commonly assessed in prenatal screening have been associated with a number of adverse perinatal and birth outcomes. However, it is not clear whether first trimester measurements of prenatal screening biomarkers are associated with subsequent risk of gestational diabetes mellitus (GDM). We aimed to systematically review and statistically summarize studies assessing the relationship between first trimester prenatal screening biomarker levels and GDM development. We comprehensively searched PubMed/MEDLINE, EMBASE, CINAHL, and Scopus (from inception through January 2018) and manually searched the reference lists of all relevant articles. We included original, published, observational studies examining the association of first trimester pregnancy associated plasma protein-A (PAPP-A) and/or free β-human chorionic gonadotropin (free β-hCG) levels with GDM diagnosis. Mean differences were calculated comparing PAPP-A and free β-hCG multiples of median (MoM) levels between women who developed GDM and those who did not and were subsequently pooled using two-sided random-effects models. Our meta-analysis of 13 studies on PAPP-A and nine studies on free β-hCG indicated that first trimester MoM levels for both biomarkers were lower in women who later developed GDM compared to women who remained normoglycemic throughout pregnancy (MD -0.17; 95% CI -0.24, -0.10; MD -0.04; 95% CI -0.07-0.01). There was no evidence for between-study heterogeneity among studies on free β-hCG (I2 = 0%). A high level of between-study heterogeneity was detected among the studies reporting on PAPP-A (I2 = 90%), but was reduced after stratifying by geographic location, biomarker assay method, and timing of GDM diagnosis. Our meta-analysis indicates that women who are diagnosed with GDM have lower first trimester levels of both PAPP-A and free β-hCG than women who remain normoglycemic throughout pregnancy. Further assessment of the predictive capacity of these biomarkers within large, diverse populations is needed.http://europepmc.org/articles/PMC6062092?pdf=render |
| spellingShingle | Brittney M Donovan Nichole L Nidey Elizabeth A Jasper Jennifer G Robinson Wei Bao Audrey F Saftlas Kelli K Ryckman First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. PLoS ONE |
| title | First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. |
| title_full | First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. |
| title_fullStr | First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. |
| title_full_unstemmed | First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. |
| title_short | First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. |
| title_sort | first trimester prenatal screening biomarkers and gestational diabetes mellitus a systematic review and meta analysis |
| url | http://europepmc.org/articles/PMC6062092?pdf=render |
| work_keys_str_mv | AT brittneymdonovan firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis AT nicholelnidey firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis AT elizabethajasper firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis AT jennifergrobinson firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis AT weibao firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis AT audreyfsaftlas firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis AT kellikryckman firsttrimesterprenatalscreeningbiomarkersandgestationaldiabetesmellitusasystematicreviewandmetaanalysis |